Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Active not recruiting 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4Stage I Prostate Adenocarcinoma AJCC v7 1Prostate Adenocarcinoma 1PSA Level Greater Than Two 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 28enzalutamide 23Specimen Handling 20apalutamide 17Androgen Antagonists 14Radiosurgery 13Radiotherapy 12Prednisone 12Docetaxel 12Abiraterone Acetate 12abiraterone 10Biopsy 10Radiation 8niraparib 6luprolide acetate gel depot 6darolutamide 6Pluvicto 6Leuprolide 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6relugolix 5gallium 68 PSMA-11 5cabazitaxel 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Nivolumab 5Gonadotropin-Releasing Hormone 5bicalutamide 4Triptorelin Pamoate 4Surveys and Questionnaires 4Radiotherapy, Intensity-Modulated 4Glutamate Carboxypeptidase II 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Prostatic Neoplasms × bicalutamide × 30 days × Clear all
NCT07593079 2026-05-18

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

Washington University School of Medicine

Phase 2 Not yet recruiting
20 enrolled
Genitourinary

Prostatic Neoplasms

NCT07455903 2026-05-13

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Baptist Health South Florida

Phase 2 Recruiting
50 enrolled
Genitourinary

Prostatic Neoplasms

NCT02531516 2026-05-08

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Aragon Pharmaceuticals, Inc.

Phase 3 Active not recruiting
1,503 enrolled
Genitourinary

Prostatic Neoplasms

NCT04513717 2026-05-04

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

NRG Oncology

Phase 3 Active not recruiting
2,753 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡